The eSMART project aims to demonstrate benefits for cancer patients using a real-time, mobile phone based remote patient monitoring system, the Advanced Symptom Management System (ASyMS). It is anticipated to greatly improve patient outcomes and delivery of care both during and after chemotherapy treatment.
The eSMART project involves 11 European and 1 American partner as well as cancer care clinicians from all partner countries. A trial will be conducted across 16 European sites with 1108 patients being recruited. Patients will be invited onto the trial, with eligibility determined by a) undergoing their first course of chemotherapy, b) for breast, colorectal or haematological cancers and c) planning to receive a minimum of 4 cycles of chemotherapy. The project is being advised by members of the European Cancer Patient Coalition to ensure that work is conducted in line with patients’ perspectives and needs.
WP1 Integration of ASyMS within different Healthcare Systems across Europe
WP2 Demonstration of the Effects of ASyMS on Patient Outcomes during Chemotherapy Treatment
WP3 Demonstration of the Sustained Effects of ASyMS in the Year Following Completion of Chemotherapy
WP4 Changes in clinical practice following the introduction of ASyMS
WP5 Predictive Risk Model to Deliver Personalised Care
WP6 Dissemination and Exploitation
The eSMART project is being conducted by the School or Health Sciences. The eSMART trial will be supported by the University of Surrey’s dedicated Clinical Trials Unit.
The project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602289.
Further information can be found at :
eSMART Website: www.esmartproject.eu
eSMART Twitter: @eSMART_EU